Sumaiya Shahjahan

Sumaiya Shahjahan

Auto-generated profile, based on publicly available information

Sumaiya Shahjahan

Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in Vision
Verified
Journal Article
Open access
PDF file
JKJeonghyun (Esther) Kwon
Jeonghyun (Esther) Kwon
CKChristie Kang
Christie Kang
AMAmirhossein Moghtader
Amirhossein Moghtader
SSSumaiya Shahjahan
Sumaiya Shahjahan
ZBZahra Bibak Bejandi
Zahra Bibak Bejandi
ADAli Djalilian
Ali Djalilian
Persistent corneal epithelial defects (PCEDs) are a challenging ocular condition characterized by the failure of complete corneal epithelial healing after an insult or injury, even after 14 days of standard care. There is a lack of therapeutics that target this condition and encourage re-epithelialization of the corneal surface in a timely and efficient manner. This review aims to provide an overview of current standards of management for PCEDs, highlighting novel, emerging treatments in this field. While many of the current non-surgical treatments aim to provide lubrication and mechanical support, novel non-surgical approaches are undergoing development to harness the proliferative and healing properties of human mesenchymal stem cells, platelets, lufepirsen, hyaluronic acid, thymosin ß4, p-derived peptide, and insulin-like growth factor for the treatment of PCEDs. Novel surgical treatments focus on corneal neurotization and limbal cell reconstruction using novel scaffold materials and cell-sources. This review provides insights into future PCED treatments that build upon current management guidelines.